Re­call re­port: Zy­dus re­calls her­pes drug af­ter crys­tal­liza­tion com­plaints; Alem­bic pulls low blood pres­sure drug for in­cor­rect la­bel­ing

It’s been a rel­a­tive­ly qui­et start to the year in terms of drug re­calls, but the FDA hit two gener­ics mak­ers late last week for man­u­fac­tur­ing is­sues.

First, Zy­dus Phar­ma­ceu­ti­cals re­called a her­pes and shin­gles drug Thurs­day af­ter com­plaints of crys­tal­liza­tion in vials.

The ad­min­is­tra­tion of crys­tal­lized acy­clovir sodi­um in­jec­tion could cause in­flam­ma­tion of the vein or blood clots, an in­crease in stroke and heart at­tack and de­creased liv­er or kid­ney func­tion, ac­cord­ing to the FDA. Zy­dus hasn’t re­ceived any re­ports of neg­a­tive re­ac­tions con­nect­ed to the crys­tal­liza­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.